Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© Cambridge University Press 2009. At all stages of development, human hemoglobin is made up of two α-like and two β-like globin chains. In embryonic life the ζ and ε genes are fully active, producing embryonic hemoglobin (ζ2 ε2). Between 6 and 8 weeks of gestation there is a switch in expression so that the α- and γ-globin genes become fully expressed, producing fetal hemoglobin (α2γ2). Finally, at around the time of birth there is a further switch from γ- to β-globin expression so that in adult red cells HbA (α2β2) predominates. In α thalassemia, the synthesis of α-globin chains is downregulated so that in fetal life there is anemia and the excess γ-globin chains form soluble tetramers (γ4) called Hb Bart's. In adult life, α thalassemia also causes anemia but, because by this time the γ to β switch is complete, the excess non–α chains assemble into β4 tetramers, called HbH. The degree of anemia and the amounts of the abnormal hemoglobins (Bart's and H) produced broadly reflect the degree to which α-globin synthesis has been downregulated. We now know that normal individuals have four α-globin genes, arranged as linked pairs of genes at the tip of each copy of chromosome 16, written in shorthand as αα/αα. α Thalassemia most commonly results from the deletion of one (-α) or both (--) α genes from chromosome 16. Carriers of α thalassemia (-α/αα and --/αα) have mild hypochromic microcytic anemia and may produce detectable amounts of Hb Bart's at birth.

Original publication





Book title

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Second Edition

Publication Date



239 - 240